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In primary care, asthma is usually assessed by means of the patients’ history regarding symptoms and simple lung-
function testing. These outcomes may, however, not be related to other estimates of asthma control such as quality
of life. In the present study quality of life was studied in relation to symptoms (visual analogue scale, VAS) and lung
function in adult patients with asthma in a primary-care setting.
In a healthcare centre in Stockholm, 405 individuals diagnosed as having asthma were identified. Out of this
number, 120 patients completed the study. Patients were categorized into four groups according to lung function
and their response to a question regarding asthma symptoms on the VAS. Quality of life was evaluated with the
Asthma Quality of Life Questionnaire (AQLQ) and current treatment was recorded.
Quality of life differed significantly between the groups with regard to all domains and overall score; overall score
was 6?0 (0?12)—(mean SEM) in group A (VAS 2, normal FEV1), 5?4 (0?24) in group B (VAS 2, low FEV1), 4?8
(0?25) in group C (VAS42, normal FEV1) and 4?6 (0?24) in group D (VAS42, low FEV1) (P50?0001). In general
a gradient, with group A having the highest and group D the lowest score, was detected. Experience of symptoms
(VAS42) was highly related to lower scores in the environmental domain (P50?0001). The correlation between
FEV1 and quality of life was generally low whereas there was a fairly good correlation between VAS and quality of
life (P50?0001 for all domains). Patients without steroid treatment had higher quality of life scores than patients
treated with steroids.
The majority of asthma patients in primary care have high quality of life scores, indicating a low prevalence of
symptoms and only slight activity limitations. Evaluation of quality of life enables a more careful grading of asthma
status. Furthermore, this measure provides information concerning asthma control that is not revealed by
spirometry and simple questions regarding symptoms.
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Asthma is a chronic disease which is most often diagnosed
and treated in primary care. The majority of patients have
mild to moderate asthma. However, there may be patients
who have moderate symptoms which may not be reflected
by impaired lung function, increased daily PEF-variability
or acute exacerbations. It is, therefore, important to
develop methods which make it possible to monitor asthma
control and detect the probably often unconscious accep-
tance of mild asthma symptoms. One instrument to
monitor patients’ well-being are standardized quality of
life questionnaires that have been increasingly recognized
during recent years. In a quality of life bibliography
published in 1989 there were no articles included thatReceived 17 April 2000 and accepted in revised form 11 September
2000. Published online 11 December 2000.
Correspondence should be addressed to: Dr Per-Olof Ehrs, Family
Medicine Stockholm, Dept of Clinical Sciences, Novum, SE - 141
57 Huddinge, Sweden. Fax: +46 8 686 61 01; E-mail: poehrs
@hotmail.com.
0954-6111/01/010022+09 $35?00/0focused on asthma-specific quality of life questionnaires (1).
Today, however, a number of disease-specific instruments
have been constructed (2). Disease-specific questionnaires
are more sensitive than general instruments for measuring
small clinical changes and may be used both for patients
with very mild asthma and for those with a more severe
disease. These disease-specific questionnaires do not esti-
mate quality of life in general and are, therefore, not helpful
when comparing the impact of different diseases.
The outcome of asthma therapy has usually been
evaluated by measuring lung function, predominantly
FEV1, in primary care as well as by specialists. Changes
in FEV1 or PEF are, however, only weakly correlated with
changes in quality of life (3–8) indicating that quality of life
and physiological outcomes focus on different aspects of the
disease. There are thus no data suggesting that quality of
life is related to airway tone in asthmatic patients. The
possibility that patients’ perceptions of quality of life can be
related to airway inflammation should not be overlooked.
Studies of quality of life in asthma have evolved during
recent years. Despite the fact that the majority of asthma
patients are treated in primary care, few quality of life# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Patients divided into four groups according to
VAS and pre-bronchodilator FEV1
FEV1475% of
predicted value
FEV175% of
predicted value
VAS-scale 0–2 A B
VAS-scale 42 C D
TABLE 2. Patients were divided into three groups with
regard to current treatment (the last 2 weeks)
I II III
No treatment or Budesonide
or BDP
Budesonide
or BDP
b2-agonist prn or 400mg/day or 4400mg/day or
b2-agonistþDSCG FP200mg/day FP 4200 mg/day
BDP: beclomethasone dipropionate; FP: fluticasone pro-
pionate; DSCG: disodium cromoglycate
QUALITY OF LIFE IN ASTHMA 23studies with these patients have thus far been conducted. In
previous studies, the majority of patients studied have been
recruited among patients who are regularly controlled by
specialists. In the present study our aims were to estimate
and describe quality of life using a disease-specific ques-
tionnaire and to measure lung function in patients who on
one or more occasions had consulted primary healthcare
facilities. Patients were first identified by means of
computerized health records, whereafter patients were
contacted by mail, inquiring whether they wished to
participate in the study (selection criterion was primary
care physicians’ diagnoses for asthma). The authors also
aimed to find out whether the quality of life questionnaire is
usable in general practice where most of the patients with
mild to moderate asthma are treated.
Material and methods
SUBJECTS
The study was conducted at a healthcare centre in central
Stockholm, Sweden. When computerization of case records
was started in 1994, the healthcare centre employed 10
doctors and had a catchment area of approximately 20 000
individuals. On 15 August 1996, when the study started,
405 persons within the area were diagnosed by a physician
as having asthma.
In the present study, asthma patients who are 18–65
years of age, were included. Exclusion criteria were
pregnancy, serious diseases such as psychiatric disease,
alcoholism, rheumatoid arthritis, cancer or chronic ob-
structive pulmonary disease (COPD). Patients who had
moved out of Stockholm or who had a poor understanding
of Swedish were also excluded. Those who did not respond
to the first letter received one reminder.
Subjects who had never smoked were classed as non-
smokers. Those who currently smoked or had stopped
smoking within the 12 months prior to the survey were
classified as smokers. Subjects who had stopped smoking
more than 12 months prior to the study were classed as ex-
smokers.
All subjects were categorized according to the response to
the question ‘Have you experienced any asthma problems
or breathing diculties during the last two weeks?’ on the
visual analogue scale (VAS). All patients had previously
experienced symptoms interpreted by a general practitioner
to be asthma. Therefore symptoms were not further defined
in the present interview, which was supposed to resemble a
common clinical consultation. The patients were then
separated into four groups depending on the outcome of
the VAS and lung-function tests (Table 1). As there is no
generally accepted cut-off limit for discriminating between
mild and moderate asthma symptoms on a VAS and the
aim was to identify patients with no or very mild symptoms
an arbitrary cut-off limit of 2 was chosen. The patients were
also categorized into three groups with regard to the
asthma treatment they had received during the last 2 weeks
prior to the first visit (Table 2).STUDY DESIGN
All patients indicated the impact of asthma symptoms on a
VAS after which a lung-function test was performed both
before and after bronchodilatation. The patients were
subsequently interviewed regarding smoking habits and
medication and they completed a disease-specific quality of
life questionnaire (2)
VISUAL ANALOGUE SCALE
On a 10 cm visual analogue scale (VAS), the patients
indicated the severity of their asthma symptoms during the
last 2 weeks. Each end of the scale indicates the range being
considered: from ‘no problems at all’ to ‘problems so bad
that I had to be admitted to hospital’.
THE ASTHMA QUALITY OF LIFE
QUESTIONNAIRE
The Asthma Quality of Life Questionnaire by Juniper et al.
was used (5). The questionnaire has 32 items, divided into
four domains: activity limitations (11 items), symptoms (12
items), emotional functions (five items) and environmental
stimuli (four items). Five of the 11 items in the activity
domain were individualized and the patients were asked to
identify five activities that were limited because of asthma.
Twenty-six activities are offered as probes to aid recall, such
as walking upstairs, hurrying, laughing or vacuuming. The
patients were asked to indicate the extent to which they
have been limited on a seven-point scale, where one
indicates maximal impairment and seven no impairment
at all.
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FEV1 and FVC were measured with a MicroLab 3300
Spirometer (Micro Medical Ltd, Rochester, Kent, U.K.)
according to the standards of American Thoracic Society.
Salbutamol (5?0mg) and ipratropium bromide (0?5mg)
were mixed and inhaled using a jet nebulizer (Aiolos,
Medicinsk Teknik AB, Karlstad, Sweden). Lung function
was measured 20min after inhalation. Reference values by
Hedenstro¨m et al. were used (9,10).
STATISTICS
Results are presented as mean values and standard error of
the mean (SEM). Comparisons were performed by the use of
variance analysis (ANOVA) with Fischers PLSD post hoc
test, Students’ t-test (two-group comparisons), simple
regression and Pearsons’ correlation coecient. A P-value
50?05 was considered significant when using ANOVA.
When correlations between quality of life and other
parameters were calculated the Bonferroni method for
multiple comparisons was used in which a P-value50?01 is
considered to be significant.
Results
Details about the patients are presented in Table 3. Out of
the 405 patients who were evaluated, 181 were excluded
according to the exclusion criteria, 145 because of age (110
subjects465 and 35 subjects518 years of age) and 36 due
to other diseases. A letter with invitation to participate in
the study was sent to the remaining 224 patients. One
reminder was sent to patients who failed to respond.
Ninety-nine (36 men) did not respond. Of these 99 patients,
42 had moved out of the area and 57 patients did not
respond for unknown reasons. The mean age of the non-
respondents was 30 (18–56) years of age among those who
had moved and 38 (18–64) years of age among those who
did not respond for unknown reasons.
Of the 125 patients who accepted to take part in the study
three did not attend, one was excluded due to pregnancy
and one due to co-operation diculties. Of the 120 patientsTABLE 3. Patients’ characteristics. DFEV1 (% pred) indicates th
inhalation of bronchodilator
Group A B
n 50 25
Sex, M/F 21/29 14/11
Mean age, years (range) 36 (21–59) 46 (26–64)
FEV1 (% pred.) 89?7 (1?2) 66?0 (2?0)
FVC (% pred.) 81?4 (1?5) 65?2 (2?0)
FEV1/FVC, % 87?6 (0?9) 78?8 (2?6)
DFEV1 (% pred.) 4?1 (0?7) 11?5 (1?3)
Smokers 8 14
Ex-smokers 14 7
Non-smokers 28 4who completed the study, 44 (37 %) were classified as non-
smokers. Lung function was impaired in smokers [FEV1
72?8 (1?4) % of predicted value] compared to ex-smokers
[FEV1 80?2 (2?6) % of predicted value, P=0?041] and non-
smokers [84?2 (1?9) % of predicted value, P=0?0007].
Inhalation of bronchodilators induced a FEV1-increase of
more than 10% of the predicted value in groups B and D,
i.e., in the groups with initial, pre-bronchodilator, FEV1
 75% of predicted value, but not in groups A and C
(Table 3). In nine patients, who had an overall quality of
life score54 and FEV1575% of predicted value the
increase in FEV1 following bronchodilatation was 48%
of predicted value. (One patient did not fulfil the
reversibility test because of an acute asthma attack
following the initial FEV1 measurement.) Three patients
reported scores 44 for all quality of life domains despite
having a FEV1540% of predicted value.
Forty-two percent of the patients qualified for group A
while 21%, 20% and 17% of the patients fell into groups B,
C and D, respectively. The patients in group A were
significantly younger than those in the other three groups
(F=5?4, P=0?002).
Quality of life overall was 6?0 (0?12) in group A, 5?4
(0?24) in group B, 4?8 (0?25) in group C and 4?6 (0?24) in
group D. Quality of life differed significantly between the
groups (activity limitation F=2?70; P=0?05, symptoms
F=13?1; P50?0001, emotion F=8?29; P50?0001, envir-
onment F=6?40; P50?001, quality of life overall F=10?6;
P50?0001). Quality of life and differences between the
groups are shown in Fig. 1. In general a gradient, with
group A having the highest score and group D having the
lowest score, was detected. This is most obvious for the
questions regarding emotional factors, while there is a
substantial overlap regarding activity limitation and
symptoms. For environmental factors, there is a clear
difference between subjects who experience symptoms
(VAS42, i.e. groups C and D), and those who do not
(groups A and B), according to the VAS (P50?0001). Only
a few patients experienced dyspnoea, wheeze or had a
troublesome cough due to asthma.
In general, the correlation between quality of life overall
estimation and the four domains (activity limitation,
symptoms, emotion and environment) and lung function,e increase in FEV1, in percent, of predicted value following
C D Total
24 21 120
6/18 7/14 48/72
42 (20–60) 43 (23–63) 40 (20–64)
87?1 (1?7) 59?6 (2?9) 79?0 (1?0)
82?2(2?4) 58?6 (3?0) 74?0 (1?0)
85?2 (1?8) 81?9 (2?9) 84?3 (0?9)
4?3 (1?0) 11?0 (1?1) 6?9 (0?6)
10 11 43
6 6 33
8 4 44
FIG. 2. Relationship between quality of life (QoL) and lung func
line is drawn at a pre-bronchodilator FEV1 of 75% of predicted
normal and impaired lung function. P-values are given without
FIG. 1. Quality of life (QoL) regarding the four domains
activity limitation, symptoms, emotion and environment
and overall quality of life estimations in the four groups.
Mean and 95% confidence intervals. &: A; &: B; *: C;
*: D.
QUALITY OF LIFE IN ASTHMA 25as assessed by FEV1, was weak, although it was significant
for symptoms (P=0?0015) and overall estimation (P=0?02,
Fig. 2). Significant correlations were found between all
quality of life estimations and symptoms assessed by the
VAS (P50?0001, Fig. 3). No significant correlation was
found between VAS and FEV1 (P40?12 in all groups, data
not shown).
In general, women had lower quality of life scores than
men with regard to all domains and overall estimation. This
difference was significant only for the environment domain
(P50?01, Fig. 4). There was no significant difference
between FEV1 in percent of predicted value between
women [80?4 (1?9) %] and men [76?8 (2?3) %, P=0?22]
Forty-five patients experienced at least five normal daily
activities to be limited due to their asthma while 38 patients
did not have any daily activity limitation due to the disease.
Limitation was mostly felt while hurrying (n=43), walking
upstairs or uphill (n=36), running upstairs or uphilltion assessed by FEV1 in 120 asthmatic patients. A vertical
value in order to arbitrarily characterize the patients into
correction for multiple comparisons.
FIG. 3. Relationship between quality of life (QoL) and symptoms assessed by a VAS in 120 asthmatic patients. A vertical line
is drawn at a VAS = 2, which was an arbitrarily chosen score to identify symptomatic and non-symptomatic patients. P-
values are given without correction for multiple comparisons.
FIG. 4. The four quality of life (QoL) domains and the
overall quality of life estimation in men and women.
Mean and 95% confidence intervals.*: Male;*: female.
26 P. O. EHRS ET AL.(n=27), jogging, exercising or running (n=26), walking
(n=26) and sleeping (n=25). Since only 45 patients had
activity limitation according to the five ‘individualized’
questions, these answers were not included in the calcula-
tion of ‘activity limitation’ and ‘overall’ assessments given
in the results and figures.
Half of the patients without symptoms (group A: 48%;
and B: 52%) and 71% of the patients with symptoms but
with normal lung function (group C) were regularly treated
with inhaled steroids. Out of the patients with symptoms
and lung-function impairment (group D) 2/3 took inhaled
steroids. Treatment is shown in Table 4. Significant
differences were found with regard to all quality of life
assessments between the treatment groups, i.e. groups
categorized by the use of inhaled steroids (activity limita-
tion F=9.39; P=0?0002; symptoms F=5?49; P=0?005;
emotion F=4?52; P=0?013; environment F=5?28;
P=0?006; quality of life overall F=9?10; P=0?0008,
TABLE 4. Treatment during the last 2 weeks in the four
patient groups. For explanations of group I, II and III see
footnote to Table 2
Group I II III
A 26 18 6
B 12 4 9
C 7 11 6
D 7 6 8
FIG. 5. Quality of life (QoL) regarding the four domains:
activity limitation, symptoms, emotion and environment
and overall quality of life estimations related to anti-
asthma treatment*: I; no inhaled glucocorticoids;*: II;
low-dose inhaled glucocorticoids; &: III; high-dose
inhaled glucocorticoids. Mean and 95% confidence
intervals.
QUALITY OF LIFE IN ASTHMA 27Fig. 5). Patients with no steroids (group I) achieved
significantly higher quality of life scores than patients
who inhaled high doses of steroids (group III), with patients
on low doses of inhaled steroids (group II) in between
(Figure 5).
Discussion
The present study shows that symptoms given on a VAS are
better related to quality of life, as assessed by the
questionnaire by Juniper et al. (2), than lung function
(FEV1). Both quality of life and the outcome of the VAS
showed a low correlation with lung function. A weak, non-
significant or a lack of correlation between lung function
and quality of life has been shown by others (3–8) but, to
our knowledge, this has not been demonstrated using
disease-specific questionnaires in patients with mild asthma
attending a primary-care unit. The most striking difference
between patients who, according to the VAS, experienced
symptoms and those who did not was the environment
domain in the quality of life questionnaire. This finding
suggests that airway responsiveness to irritating stimuli are
more closely related to patients’ experience of symptoms
and poor asthma control than lung function as assessed byspirometry. It would thus be of interest to study the
relationship between bronchial responsiveness, preferably
to indirect stimuli, and the outcome of quality of life
assessments.
A distinction between the groups was also found with
regard to the emotional domain. Those who indicated a low
symptom score on the VAS had the highest quality of life
score. The difference between the groups indicates, how-
ever, that lung function may be related to the outcome of
quality of life on the emotional domain. No consistent
pattern could be detected regarding the symptoms and
activity domains. The weak correlation between lung
function assessed by FEV1 and symptoms/quality of life,
is also supported by the findings in group C, i.e. the patients
with symptoms but with normal lung function. Among
these patients more than two out of three patients inhaled
steroids on a regular basis. It could be assumed that the
steroids were more potent in normalizing lung function
than in improving symptoms and quality of life among
these patients. This finding is supported by the results of
van Schayck et al. (11). A relationship between lower
quality of life scores and high consumption of inhaled
steroids in primary-care asthma patients has been demon-
strated previously (12), reflecting most probably the fact
that higher doses of steroids are prescribed to patients with
more severe disease.
There is no ‘golden standard’ for measuring asthma
severity. The correlation between frequently used indices
(e.g. spirometry, PEF-variability etc.) and quality of life is
weak. The need for data on the impact of asthma on every-
day life cannot, therefore, be satisfied by the use of lung-
function measurements. The quality of life questionnaire
provides data on asthma status which is not obtained by
conventional measurements of lung function and simple
questions regarding symptoms etc. Quality of life ques-
tionnaires could be an appropriate tool for evaluating
asthma status in primary care. It is, however, rather time-
consuming and may therefore be of limited value in daily
use when communicating with patients. However, a shorter
and simpler, self-administered, 15-item Mini-Asthma Qual-
ity of Life Questionnaire has recently been developed (13).
Many healthcare centres have nurse-administered asthma
clinics in which an extended role for active management of
asthma and the mini-asthma quality of life questionnaire
may be used. In such a setting, the questionnaire can be
used as a standardized method for evaluation of asthma
severity in primary care. In the future, interactive pro-
grammes for asthma patients may be developed as are being
used for diabetes patients at present.
A change of 0?5 in the score both for overall activities
and for individual domains represents a ‘minimal important
difference’ (14). A change of approximately 1?0 represents a
moderate change and changes41?5 represent great change
in quality of life (14). The authors do not know of any
studies that have addressed what is a clinically significant
difference in quality of life between groups. However, it is
reasonable to assume that the same difference (0?5) could be
used also for inter-individual (between groups) compar-
isons. In the present study, the difference in quality of life
overall was approximately the same between groups A and
28 P. O. EHRS ET AL.B (0?6) and between groups B and C (0?6), while the
difference between groups C and D was smaller (0?2). Thus,
asthmatic patients, who did not report symptoms on the
VAS, differed ‘significantly’ when lung function was taken
into consideration (groups A and B). This finding, together
with the weak, although significant correlation for symp-
toms and quality of life overall estimation, indicates that
lung function assessed by FEV1 may have some minor
influences on the patients’ perceptions of their disease.
However, in patients with symptoms (assessed by VAS),
reduced lung function did not lead to further quality of life
impairment (groups C and D). The high negative correla-
tion between VAS and quality of life, especially symptoms
and overall estimation, is interesting and indicates that the
VAS is a better predictor of the quality of life outcome than
is lung function.
It should be noted that some of the patients in the present
study may not be asthmatics but are suffering from chronic
obstructive pulmonary disease (COPD) because of long-
term smoking. However, we found a bronchodilatation of
 8% of predicted FEV1 in the patients who had a quality
of life score lower than 4 and FEV1575% of predicted
value and a reversibility of more than 10% of predicted
FEV1 in the three patients who had a quality of life score
higher than four and FEV1 below 45% of predicted value.
These results showed that the patients in the present study
had reversible airway obstruction, suggesting that most of
them had asthma and not COPD. On the other hand, the
finding of impaired lung function in smokers compared
with non-smokers and ex-smokers suggests that COPD
induced by smoking may have been present in some of the
patients.
It is also clear from the present study that there are
patients who do not report symptoms despite a substan-
tially impaired lung function, sometimes called poor
perceivers. A probable explanation for this phenomenon
is adaptation to a sedentary lifestyle. This assumption is
supported by the finding of a total lack of correlation
(r=0?12, implying an explained variability of 52%)
between the activity limitation domain and FEV1.
Despite no gender difference in lung function, females
had, in general, lower quality of life scores although this fell
out significantly only for the environment domain. This was
also reflected by the assessment of symptoms using the
VAS. In total 60% of the participants were female while
67% in group D and 75% in the group C were women. A
tendency towards higher symptom scores in asthmatic
women compared to men with asthma was described by
Juniper et al. when the quality of life questionnaire was
constructed (15). Women seem to be more annoyed by
physical climate factors than men and seem to run the risk
of ‘sick building syndrome’ to a higher extent than men
(16–19). It has been claimed that this gender difference can-
not be explained by predisposing factors such as prevalence
of asthma or rhinitis (19). The reason for the gender
difference is not clear. Some authors claim that it is not the
result of a tendency for higher reporting among women (20)
whereas others claim that this is the case (18). There is no
clear explanation for the small gender differences found in
the present study, but the results are in agreement withother authors who demonstrated that asthmatic women in
general had lower quality of life scores than men assessed
by a general quality of life questionnaire (SF-36) (21,22).
The proportion of smokers and ex-smokers were higher
in groups B, C and D than group A, indicating a relation
between smoking and asthma, not only with regard to lung
function but also to well-being and symptoms. It is notable
that, despite symptoms (groups C and D), approximately
half of the patients continued to smoke, which is a definite
challenge for doctors.
Out of 224 eligible patients, 99 were not reached. In this
area of Stockholm most apartments are small and there is a
20% annual turnover of people which leads to a relatively
low response rate as was the case in an urban population
study by Marks et al. (12). As could be anticipated, the
mean age of those who had moved was lower (30 years)
than for those who did not respond for unknown reasons
(38 years). The impression from the clinical records at the
healthcare centre gave no reason to believe that the severity
of asthma was different among the non-respondents when
compared to the participants, although such a possibility
cannot be totally excluded.
In conclusion, it was found that most of the asthma
patients controlled in general practice in an inner-city area
seem to have good asthma control. More than 85% of the
patients in group A and more than 60% of the patients in
group B had a quality of life ‘overall’ score higher than 5?0,
indicating that these patients did not feel their asthma was
troublesome. These findings are supported by some
investigators (12), in contrast to those reported by van
Schayck et al. who found impaired quality of life in asthma
patients compared with the general population (23). Half of
these patients were not treated with steroids. The results
suggest that there may be no indication for regular
treatment in these patients. It is, however, important to
emphasize that the authors, based on the results of the
present study, are unable to draw any conclusions
regarding the development and the long-term outcome of
asthma. The value of early asthma treatment in the long run
has to be evaluated in longitudinal studies.
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Quality of Life Questionnaire according to Juniper et al.
Am Rev Respir Dis 1993; 147: 832–838.
Domain Question
Activities 11, 19, 25, 28, 31, 32
Symptoms 6, 8, 10, 12, 14, 16, 18, 20,
22, 24, 29, 30
Emotions 7, 13, 15, 21, 27
Environment 9, 17, 23, 26
6. How much discomfort or distress have you felt over
the last 2 weeks as a result of chest tightness?
7. In general, how often during the last 2 weeks have you
felt concerned about having asthma?8. How often during the past 2 weeks did you feel short
of breath as a result of your asthma?
9. How often during the past 2 weeks did you experience
asthma symptoms as a result of being exposed to
cigarette smoke?
10. How often during the past 2 weeks did you experience
a wheeze in your chest?
11. How often during the past 2 weeks did you feel you
had to avoid a situation or environment because of
cigarette smoke?
12. How much discomfort or distress have you felt over
the past 2 weeks as a result of coughing?
13. How often during the past 2 weeks did you feel
frustrated as a result of your asthma?
30 P. O. EHRS ET AL.14. How often during the past 2 weeks did you experience
a feeling of chest heaviness?
15. How often during the past 2 weeks did you feel
concerned about the need to take medication for your
asthma?
16. How often during the past 2 weeks did you feel the
need to clear your throat?
17. How often during the past 2 weeks did you experience
asthma symptoms as a result of being exposed to dust?
18. How often during the past 2 weeks did you experience
diculty breathing out as a result of your asthma?
19. How often during the past 2 weeks did you feel you
had to avoid a situation or environment because of
dust?
20. How often during the past 2 weeks did you wake up in
the morning with asthma symptoms?
21. How often during the past 2 weeks did you feel afraid
of not having your asthma medication available?
22. How often during the past 2 weeks were you bothered
by heavy breathing?
23. How often during the past 2 weeks did you experience
asthma symptoms as a result of the weather or air
pollution outside?
24. How often during the past 2 weeks have you been
woken at night by your asthma?25. How often during the past 2 weeks have you had to
avoid or limit going outside because of the weather or
air pollution?
26. How often during the past 2 weeks did you experience
asthma symptoms as a result of being exposed to
strong smells or perfume?
27. How often during the past 2 weeks did you feel afraid
of getting out of breath?
28. How often during the past 2 weeks did you feel you
had to avoid a situation or environment because of
strong smells or perfume?
29. How often during the past 2 weeks has your asthma
interfered with getting a good night’s sleep?
30. How often during the past 2 weeks have you had the
feeling of fighting for air?
31. Think of the overall range of activities that you would
have liked to have done during the past 2 weeks. How
much has your range of activities been limited by your
asthma?
32. Overall, among all the activities that you have done
during the past 2 weeks, how limited have you been by
your asthma?
